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ABSTRACT
Heparin-Induced Thrombocytopenia (HIT) is a disastrous, potentially devastating immune-mediated adverse drug reaction resulted 
in the formation of antibodies which activate platelets in the presence of heparin. Here, we presented an exemplifying case of a 
45-year-old male patient, a known case of Deep Venous Thrombosis admitted in Emergency Department with complaints of left groin 
pain along with passing bloody clot in urine for past 5 days. The patient was diagnosed as Renal Artery Thrombosis with the help 
of radiological findings and was treated with Inj. Heparin. Thrombocytopenia developed on the first day of therapy and confirmed 
with Heparin PF4 IgG ELISA Immunoassay. The patient switched to inj. Argatroban and later changed to oral anticoagulant therapy. 
Platelet count gradually came to normal upon stoppage of Inj. Heparin. To avoid a catastrophic outcome, heparin should be stopped 
before initiating proper management.
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Heparin is widely used for thromboprophylaxis or treatment in many clinical situations, including acute coronary syndromes, venous thromboembolism, atrial 
fibrillation, peripheral occlusive disease, dialysis, and during 
extracorporeal circulation. Approximately, one-third of the 
hospitalized patients in the USA, or about 12 million patients per 
year receive heparin [1].
Heparin-Induced Thrombocytopenia (HIT) is a dangerous, 
potentially lethal, immunologically mediated adverse drug 
reaction to unfractionated heparin (UFH) or less commonly 
with low molecular weight heparin (LMWH). The prevalence 
of HIT ranges from 0.1%-5.0% of the patients receiving 
heparin, with 35-50% of the patients developing thrombosis [2]. 
Approximately, 10% to 20% of patients will develop transient 
mild thrombocytopenia after 1 to 4 days of heparin therapy. The 
platelet count rarely goes below 100,000/ml, often becomes 
normal despite further heparin administration and is generally 
without clinical sequale [3].
CASE REPORT
A 42-year-old male patient was admitted in the emergency with 
the complaints of radiating left groin pain along with passing 
bloody clot in urine for the past 5 days. On exploration of the 
patient history, it was found that he had a past history of Deep 
Venous Thrombosis and was admitted for pulmonary embolism 
8 months back. 
On the time of admission, the vitals were stable and the 
patient physical parameters were found to be normal except mild 
abdominal swelling with distension. Laboratory finding shows 
that haemoglobin: 7.4g/dl, total count: 13,720ccmm, Platelet 
count: 90,000, erythrocyte sedimentation rate (ESR): 103mm/
Hr, plasma Fibrinogen: 675mg% and Lactate Dehydrogenase: 
1106U/L. 
The ultrasound examination reveals non-excreting right 
kidney with perinephric fat stranding, wedge-shaped arterial 
perfusion with a hypodense filling defect in the renal vein 
suggestive of venous infractions and acute renal vein thrombosis. 
Sub-acute thrombosis of the infra-hepatic abdominal inferior 
vena cava involving the whole length for about 13cm with chronic 
deep venous thromboses of bilateral common iliac, external and 
internal vein with pelvic venous collaterals, sub-acute to chronic 
thrombus with recanalization of the both visualized portion of the 
common femoral vein.
To remove the thrombus, thromboaspiration along with renal 
vein balloon angioplasty was done with the help of Ultrasound 
guidance. A 10mg Alteplase bolus was given to the internal 
jugular vein over 20minutes, the only 20ml of clot removed and 
repeated with 5mg bolus but it went unsuccessful. So, low dose 
Heparin protocol was started with a loading dose of 4000 unit 
followed by maintenance dose of 800unit/hr, which is calculated 
based on the patient weight of 65kg, on regular monitoring of 
activated Partial Thromboplastin Time (aPTT).
The patient was treated for 4 days with regular monitoring of 
aPTT, platelet, Internalised Normalised Ratio (INR) and prothrombin 
time (Table 1). The patient platelet counted started declining which 
reached the lowest level of 15,000Cell/mm [3] (Figure 1). So heparin 
was stopped and to access HIT, we used 4 T’s pre-test scoring 
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system and HIT expert probability score (HEP) (Table 2 and 3). 
Heparin-Induced Thrombocytopenia can be assessed using the 
pre-test probability score and confirmed using HIT laboratory 
assays (Table 4).
Because of the lowering platelet level, 1 unit of Platelet was 
given as management to normalize the platelet level. Platelet 
count was gradually raised to a normal level within 6days after 
the stoppage of inj. Heparin. Instead of Heparin, Inj. Argatroban 
130mcg/min infusion was given to the patient with aPTT 
monitoring, every 3hrs and the dose was adjusted to maintain 
the level within 1.5-3 times the base i.e. between 70-100seconds. 
After 5 days, Inj. Argatroban was switched to oral therapy with 
starting of a minimum dose of Tab. Warfarin 1mgand the dose 
was adjusted with INR. The patient was fully recovered after10 
days in the critical care unit and later shifted to the ward and 
thereby discharged with a prescription of Tab. Warfarin 4mg with 
the advice of regular monitoring of INR.
DISCUSSION
Heparin-induced thrombocytopenia (HIT) is a potentially 
devastating immune-mediated adverse drug reaction caused 
by the emergence of antibodies that activate platelets in the 
presence of heparin. It is the most important and most frequent 
drug-induced type of thrombocytopenia. If unrecognized, it 
is associated with significant morbidity and mortality [1]. HIT 
may develop in two distinct forms: type I and type II. HIT type 
I (also known as heparin-associated thrombocytopenia) is a non-
immunologic response to heparin treatment, mediated by a direct 
interaction between heparin and circulating platelets causing 
platelet clumping or sequestration. HIT type I affects up to 10% 
of patients, usually occurs within the first 48–72 h after initiation 
of heparin treatment and is characterized by mild and transient 
thrombocytopenia (rarely,100 000/mm3), often returning to 
normal within 4 days once the heparin is withdrawn. Whereas 
HIT type II is immune-mediated and associated with a risk of 
thrombosis [4].
In the present case, the patient had a history of renal artery 
thrombosis which was treated with Heparin. The treatment failure 
resulted in the left renal nephrectomy. Within 100days of heparin 
therapy, the patient got readmitted with similar complaints and 
diagnosed as right-sided renal artery thrombosis and after the 
initiation of heparin therapy on the first day itself, the patient 
developed thrombocytopenia. It was assessed with the help of 
Table 1: Changes in the PLT count, aPTT and INR values of the patient 
Days I II III IV V VI VII X XII
PLT 90,000 75,000 30,000 20,000 15,000 30,000 45,000 90,000 1,48,000
APTT 36 36 55 55 123 56 33 32 32
Table 2: The 4 T’s Pre-test Scoring System for Heparin-Induced Thrombocytopenia [5]
Clinical Parameters Score Clinical description of the presentation
Thrombocytopenia 2 Platelet count fall > 50%, but lowest platelet count ≥ 20,000 mm3
Timing (of platelet count fall or thrombosis) 2 Platelet fall within 1 day of the start of heparin within 5-30 days
Thrombosis 2 New thrombosis
Other cause of platelet decline 2 No alternative explanation for platelet fall is evident
Composite Score 8 High Risk
Figure 1: Change in the Platelet count of the patient from day 1 of heparin therapy.
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Pre-test Risk and Probability Score in which 4Ts Score and HIT 
Expert Probability (HEP) Score got values of 8 and 6 showed a 
high risk of developing Thrombocytopenia [5]. The confirmation 
test used here is Heparin PF4 IgG ELISA Immunoassay screen, 
in which the test confirmed thrombocytopenia with a percentage 
probability of 53.3%.
After the verification, heparin was stopped and started inj. 
Argatroban with an initial infusion dose of 130mcg/min (2mcg/
kg/min) gradually increases up to a steady state of aPTT within 
1.5- 3 times the base i.e. between 70-100seconds. After 5 days of 
Argatroban therapy, it was switched to oral therapy i.e. Tab. Warfarin 
2mg with reducing the dose of inj. Argatroban 2mcg/kg/min with 
regular monitoring of INR [6] and the patient was discharged with 
Tab. Warfarin 4mg once daily with proper a follow-up of INR ratio.
CONCLUSION
Heparin-induced thrombocytopenia (HIT) is the most commonly 
facing immunological disorder in hospitalized patients over the 
past 6 decades. Since the initial time of the description, studies 
were encountered to analyze the pathogenesis, complication and 
proper management of HIT, which help to tackle the disease on its 
initial stage I documented this case to make an impact to solidify 
HIT’s place in the differential diagnosis of Thrombocytopenia.
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Table 3: Heparin-Induced Thrombocytopenia Expert Probability (HEP) Score [5]
Clinical Parameters Score Clinical factor and presentation
The magnitude of fall in platelet count 1 30 - 50%
The timing of fall in platelet count 3 Previous heparin exposure in the last 100days
Nadir platelet count 2 >20,000
Thrombosis 2 Progression of pre-existing arterial or venous thrombosis while on heparin
Skin necrosis 0 Not applicable
Acute systemic reaction 0 Not applicable
Bleeding 0 Not applicable
Other causes of thrombocytopenia 0 Not applicable
Composite Score 6 High Risk
Table 4: HIT screen (Heparin PF4 IgG ELISA Immunoassay) [5]
Optical Density Percentage 
Probability of 
Clinical HIT 
Result 
1.40 53.3% Positive
